AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02646267
Drug: standard intensity warfarin
DrugBank: Warfarin (DB00682)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: target international normalised ratio(INR) was 2.1-3.0
Trial: NCT02646267
Drug: dabigatran etexilate
RxNorm normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 110mg, twice a day, oral
Trial: NCT01793519
Drug: Etanercept
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subcutaneous
Trial: NCT03101085
Drug: S-equol and Placebo
RxNorm normalized name: S-equol
DrugBank: Equol (DB11674)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-equol is an estrogen receptor β (ERβ) agonist. Provided in capsules. The placebo is a matched pill that cannot be distinguished from the active S-equol.
Trial: NCT03101085
Drug: Placebo and S-equol
RxNorm normalized name: S-equol
DrugBank: Equol (DB11674)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-equol is an estrogen receptor β (ERβ) agonist. Provided in capsules. The placebo is a matched pill that cannot be distinguished from the active S-equol.
Trial: NCT00067782
Drug: Atazanavir (immediate switch)
DrugBank: Atazanavir (DB01072)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Capsules, Oral, 400mg, Once daily, 48 weeks.
Trial: NCT01793519
Drug: Infliximab
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Infusion
Trial: NCT01793519
Drug: Adalimumab
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subcutaneous
Trial: NCT02494284
Drug: Clopidogrel
RxNorm normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 6-month DAPT followed by clopidogrel monotherapy
Trial: NCT02494284
Drug: Aspirin plus clopidogrel
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: standard long-term dual antiplatelet strategies (24-month DAPT followed by aspirin monotherapy)
Trial: NCT00827034
Drug: Warfarin
RxNorm normalized name: Warfarin
DrugBank: Warfarin (DB00682)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A: a single oral dose of warfarin 25 mg administered on Day 1 of the relevant dosing period, as tablets.
Trial: NCT00827034
Drug: Dimebon
RxNorm normalized name: Dimebon
DrugBank: Latrepirdine (DB11725)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B is oral doses of Dimebon 10 mg TID on Days 1 7 and Dimebon 20 mg TID on Days 8 17, with co administration of a single oral dose of warfarin 25 mg on Day 12 of the relevant dosing period, both as tablets
Trial: NCT00827034
Drug: Warfarin
RxNorm normalized name: Warfarin
DrugBank: Warfarin (DB00682)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: B is oral doses of Dimebon 10 mg TID on Days 1 7 and Dimebon 20 mg TID on Days 8 17, with co administration of a single oral dose of warfarin 25 mg on Day 12 of the relevant dosing period, both as tablets
Trial: NCT02108951
Drug: Nilotinib
RxNorm normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nilotinib 150mg hard gelatin capsules taken orally
Trial: NCT02175173
Drug: Rufinamide
RxNorm normalized name: Rufinamide
DrugBank: Rufinamide (DB06201)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Administration of Inovelon 100mg or 200mg Tablets
Trial: NCT00093769
Drug: bortezomib + rituximab
RxNorm normalized name: Bortezomib
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Arm I: Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Patients also receive rituximab IV on days 1, 8, and 15 of course 1 only and on day 1 of course 2 only. Treatment with repeats every 21 days for up to 5 courses in the absence of disease progression or unacceptable toxicity.~* Arm II: Patients receive bortezomib IV over 3-5 seconds on days 1, 8, 15 and 22. Patients also receive rituximab IV on days 1, 8, 15, and 22 of course 1 only. Treatment repeats every 35 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.~Patients in either arm may crossover to the other arm if treatment is found to be ineffective.
Trial: NCT01761747
Drug: ponatinib
RxNorm normalized name: Ponatinib
DrugBank: Ponatinib (DB08901)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03877718
Drug: Arm 3: Sumatriptan Succinate 100 mg capsule
DrugBank: Sumatriptan (DB00669)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One capsule of sumatriptan succinate 100 mg
Trial: NCT03877718
Drug: Arm 4: Promethazine HCl 18.75 mg
DrugBank: Promethazine (DB01069)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One capsule of promethazine HCl 18.75 mg
Trial: NCT03877718
Drug: Arm 5: Promethazine HCl 37.5 mg
DrugBank: Promethazine (DB01069)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One capsule of promethazine HCl 37.5 mg
Trial: NCT00421252
Drug: clopidogrel 600 mg
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Clopidogrel load \> 2hrs pre-angiography
Trial: NCT01985126
Drug: Daratumumab 16 mg/kg (Part 1)
DrugBank: Daratumumab (DB09331)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Daratumumab 16 mg/kg administered at weekly intervals (QW) for 8 weeks, then every 2 weeks (Q2W) for an additional 16 weeks, then every 4 weeks (Q4W) thereafter by intravenous infusion
Trial: NCT01985126
Drug: Daratumumab 8 mg/kg (Part 1)
DrugBank: Daratumumab (DB09331)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Daratumumab 8 mg/kg every 4 weeks (Q4W) continuously by intravenous infusion
Trial: NCT01985126
Drug: Methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered in prophylactic doses intravenously (or equivalent in accordance with local standards) prior to and after study drug administration. Intravenous administration is preferred, but oral steroids may be substituted
Trial: NCT01985126
Drug: Diphenhydramine
RxNorm normalized name: Diphenhydramine
DrugBank: Diphenhydramine (DB01075)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 25 to 50 mg administered in prophylactic doses by mouth (or equivalent in accordance with local standards) prior to and after study drug administration.
Trial: NCT01985126
Drug: Daratumumab (Part 2)
DrugBank: Daratumumab (DB09331)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Based on the Part 1 response rate, Group A or B treatment will be selected as the treatment regimen for participants enrolled in Part 2.
Trial: NCT03179839
Drug: sertraline, fluvoxamine
DrugBank: Fluvoxamine (DB00176)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The participants can be adjustable once a week dose and the maximum dose does not exceed the maximum amount of instructions. And benzodiazepine drugs also can be used by the OCD patients with sleep disorders, but not be used continuously for more than two weeks. Besides this, other psychotropic drugs are not allowed to use. The use of drugs in this study are commonly used drugs with good safety, and its common adverse reactions include dry mouth, constipation, nausea, indigestion, dizziness, fatigue, sweating and so on.
Trial: NCT06163755
Drug: Methylprednisolone 40 MG Injection
RxNorm normalized name: methylprednisolone 40 MG Injection
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intra-articular knee injection will be performed in patient with knee osteoarthritis who meets inclusion criteria. After Random assignment Patient will either get Intra-articular Morphine with Bupivacaine or Depomedrol with Bupivacaine.
Trial: NCT03825380
Drug: Bimatoprost
RxNorm normalized name: Bimatoprost
DrugBank: Bimatoprost (DB00905)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Eyedrops
Trial: NCT02532660
Drug: Escitalopram 10mg
RxNorm normalized name: Escitalopram 10mg Oral tablet
DrugBank: Escitalopram (DB01175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Escitalopram 10mg (1 pill once a day)
Trial: NCT02221180
Drug: Canagliflozin and Metformin Immediate Release (IR) Fixed Dose Combination [FDC]
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Participants will receive 1 IR FDC tablet containing canagliflozin 150 mg and metformin 500 mg orally under fed or fasted condition in each treatment period as per treatment sequence.
Trial: NCT02221180
Drug: Canagliflozin
RxNorm normalized name: Canagliflozin
DrugBank: Canagliflozin (DB08907)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will receive canagliflozin 150 mg (50 mg+100 mg oral tablet) under fed or fasted condition in each treatment period as per treatment sequence.
Trial: NCT02221180
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Participants will receive metformin 500 mg tablet orally under fed or fasted condition in each treatment period as per treatment sequence.
Trial: NCT00067782
Drug: Atazanavir (Week 24 switch)
DrugBank: Atazanavir (DB01072)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Capsules, Oral, 400mg, Once daily, 48 weeks.
Trial: NCT02532660
Drug: Escitalopram Placebo
DrugBank: Citalopram (DB00215)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Escitalopram Placebo (1 pill once a day)
Trial: NCT01276457
Drug: Everolimus 0.25 and 0.75 mg tablets
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The dose of everolimus for each patient was adjusted to achieve the target everolimus blood level range. Everolimus blood trough level was measured 5 days after any dose adjustment to verify that the blood level was within the desired target level range.
Trial: NCT01276457
Drug: Cyclosporine very low dose (150-300 ng/mL) microemulsion
RxNorm normalized name: cyclosporine microemulsion
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The dose of cyclosporine for each patient was adjusted to achieve the target cyclosporine blood level. Cyclosporine dose adjustments were based on drug blood level determined from whole blood samples taken 2 hours (± 10 min) after the morning dose.
Trial: NCT01276457
Drug: Cyclosporine low dose (350-500 ng/mL) microemulsion
RxNorm normalized name: cyclosporine microemulsion
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The dose of cyclosporine for each patient was adjusted to achieve the target cyclosporine blood level. Cyclosporine dose adjustments were based on drug blood level determined from whole blood samples taken 2 hours (± 10 min) after the morning dose.
Trial: NCT00093821
Drug: tanespimycin
RxNorm normalized name: Tanespimycin
DrugBank: Tanespimycin (DB05134)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00498355
Drug: Ranibizumab
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 0.5 mg of ranibizumab by intravitreal injection at baseline and at monthly intervals for the following two months for a total of 3 injections. Afterwards, PRN injections for 9 months.
Trial: NCT01555125
Drug: secukinumab 150 mg
RxNorm normalized name: secukinumab 150 MG/ML
DrugBank: Secukinumab (DB09029)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: After the data base lock of week 52 data has been performed, subjects will receive secukinumab 150 mg treatment as open label for the remainder of the extension treatment period
Trial: NCT01555125
Drug: secukinumab 300 mg
RxNorm normalized name: secukinumab 300 MG in 2 ML Auto-Injector
DrugBank: Secukinumab (DB09029)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: After the data base lock of week 52 data has been performed, subjects will receive secukinumab 300 mg treatment as open label for the remainder of the extension treatment period
Trial: NCT01204255
Drug: lorazepam
RxNorm normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given topically
Trial: NCT01204255
Drug: diphenhydramine hydrochloride
RxNorm normalized name: Diphenhydramine Hydrochloride
DrugBank: Diphenhydramine (DB01075)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given topically
Trial: NCT01204255
Drug: haloperidol
RxNorm normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given topically
Trial: NCT03953261
Drug: Curcumin supplement
DrugBank: Cumin (DB10864)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention is 2 grams of curcumin supplement per day
Trial: NCT02011126
Drug: Imetelstat Sodium
RxNorm normalized name: imetelstat sodium
DrugBank: Imetelstat (DB14909)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT04644354
Drug: Nifedipine 10 mg
RxNorm normalized name: nifedipine 10 MG
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: For both groups, when preterm labor is diagnosed, 10 mg capsule will be given sublinguially and if it is not effective in 1 hour, the same dose will be repeated again, and the same regimen will be repeated every day till preterm labor ends or proceed to a preterm birth.
Trial: NCT01404572
Drug: Atazanavir (current formulation)
DrugBank: Atazanavir (DB01072)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Solution, oral, atazanavir 15 mg/5 mL with 10% aspartame, single dose
Trial: NCT01404572
Drug: Atazanavir, powder for oral use 1 (POU1)
DrugBank: Atazanavir (DB01072)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Solution, oral, atazanavir 15 mg/5 mL with 4.2% aspartame, single dose
Trial: NCT01404572
Drug: Atazanavir (POU2)
DrugBank: Atazanavir (DB01072)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Solution, oral, atazanavir 15 mg/5 mL with 4.2% aspartame and sucralose, single dose
Trial: NCT02940990
Drug: two-drug chemotherapy containing platinum, including carboplatin/Cisplatin + pemetrexed/docetaxel/paclitaxel/etoposide/gemcitabine/vinorelbine/albumin-bound paclitaxel
DrugBank: Vinorelbine (DB00361)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: two-drug regimen
Trial: NCT03867734
Drug: Aztreonam
RxNorm normalized name: Aztreonam
DrugBank: Aztreonam (DB00355)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2g IM Aztreonam
Trial: NCT03609827
Drug: Melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02265237
Drug: ombitasvir/paritaprevir/ritonavir
RxNorm normalized name: ombitasvir/paritaprevir/ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: tablets
Trial: NCT02265237
Drug: ribavirin
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: tablets
Trial: NCT00650546
Drug: Exenatide
RxNorm normalized name: Exenatide
DrugBank: Exenatide (DB01276)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5 mcg twice a day titrated to 10 mcg twice a day
Trial: NCT02450994
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01344460
Drug: Gadobutrol (Gadovist, BAY86-4875)
RxNorm normalized name: Gadobutrol
DrugBank: Gadobutrol (DB06703)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: a single bolus injection of approx. 0.1mmol/kg
Trial: NCT04917679
Drug: Eltrombopag plus diacerein
DrugBank: Eltrombopag (DB06210)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: In the combination group, eltrombopag will be administered orally at an initial dose of 75mg daily for 14 days, and diacerein will be given orally at an initial dose of 50mg bid concomitantly for 14 days (D1-D14). During treatment period, treating physicians will modify the dosage of trial treatment to maintain participants' platelet count at the range of 50 - 150 × 10\^9/L as follows: (1) if platelet count is less than 150 × 10\^9/L, continue the original treatment (eltrombopag 75mg daily plus diacerein 50mg bid); (2) if platelet count is between 150 × 10\^9/L to 250 × 10\^9/L, the treatment will be modified to eltrombopag 50mg daily plus diacerein 50mg bid; (3) if platelet count is over 250 × 10\^9/L, original treatment (both eltrombopag and diacerein) need to be stopped, and platelet count should be reexamined every other day, and the treatment (eltrombopag 50mg daily plus diacerein 50mg bid ) will be restarted until platelet count is below 100 × 10\^9/L.
Trial: NCT04917679
Drug: Eltrombopag
RxNorm normalized name: Eltrombopag
DrugBank: Eltrombopag (DB06210)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: In the monotherapy group, eltrombopag also will be administered orally at an initial dose of 75mg daily for 14 days (D1-D14), and the individualized dosage could be modified by treating physicians to maintain participants' platelet count between 50 × 10\^9/L to 150 × 10\^9/L.
Trial: NCT04128579
Drug: Itolizumab [Bmab 600]
DrugBank: Itolizumab (DB16207)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EQ001
Trial: NCT03060603
Drug: Erythropoietin
RxNorm normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant Human Erythropoietin, three times in a week, until the correction of anemia, approximately two months.
Trial: NCT00507793
Drug: Sirolimus
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00507793
Drug: Cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00113438
Drug: Combretastatin A-4 Phosphate + Paclitaxel + Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Combretastatin A-4 Phosphate is administered IV at 45 mg/m2 or 60 mg/m2 on Days 1, 8 and 15 followed by paclitaxel (3 hour infusion at 200 mg/m2) and carboplatin (1 hour infusion at AUC = 6) on Day 2 of each cycle. The treatment cycle is 21 days with a maximum of 21 days. Following cycle 6, subjects that have not progressed may continue on CA4P monotherapy, which will be administered at 45 mg/m2 or 60 mg/m2 on Days 1 and 8 with rest on Day 15, repeated every 21 days until disease progression.
Trial: NCT00006060
Drug: standard gadolinium contrast
RxNorm normalized name: gadolinium
DrugBank: Gadolinium (DB12091)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00883480
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel 75 mg/day 1 x 4 cycles
Trial: NCT02386566
Drug: natalizumab
RxNorm normalized name: Natalizumab
DrugBank: Natalizumab (DB00108)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: As described in the treatment arm
Trial: NCT03387852
Drug: Dupilumab
RxNorm normalized name: Dupilumab
DrugBank: Dupilumab (DB12159)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pharmaceutical form: Solution for Injection, Route of administration: SC
Trial: NCT03387852
Drug: Fluticasone or Fluticasone/salmeterol combination
DrugBank: Salmeterol (DB00938)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pharmaceutical form: Aerosol, dry powder, Route of administration: Inhaled
Trial: NCT03387852
Drug: Placebo for dupilumab
DrugBank: Dupilumab (DB12159)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pharmaceutical form: Solution for Injection, Route of administration: SC
Trial: NCT00883480
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel-Cisplatin 75 mg/day 1 x 4 cycles
Trial: NCT00883480
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cisplatin 75 mg/ day 1 x 4 cycles~Gemcitabine 1250 mg/ day 1 and 8 x 4 cycles
Trial: NCT00883480
Drug: Erlotinib
RxNorm normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Erlotinib 150 mg/day x 21 days
Trial: NCT02133846
Drug: TPI-287 20 mg/m2
DrugBank: TPI-287 (DB17168)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg/m2 of TPI-287 diluted with 500mL 0.9% sodium chloride. TPI-287 is a microtubule inhibitor belonging to the taxane diterpenoid (taxoid) family, and specifically to the abeotaxane class
Trial: NCT02133846
Drug: TPI-287 6.3 mg/m2
DrugBank: TPI-287 (DB17168)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6.3 mg/m2 of TPI-287 diluted with 500mL 0.9% sodium chloride. TPI-287 is a microtubule inhibitor belonging to the taxane diterpenoid (taxoid) family, and specifically to the abeotaxane class
Trial: NCT00098124
Drug: milnacipran hydrochloride
RxNorm normalized name: Milnacipran Hydrochloride
DrugBank: Milnacipran (DB04896)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02269293
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02269293
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02269293
Drug: Selinexor
RxNorm normalized name: Selinexor
DrugBank: Selinexor (DB11942)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02121847
Drug: cyclosporine 0.05% ophthalmic emulsion
RxNorm normalized name: Cyclosporine 0.05% Ophthalmic Emulsion
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine 0.05% ophthalmic emulsion (Restasis®) eye drops administered twice daily for 6 months.
Trial: NCT02121847
Drug: carboxymethylcellulose-based lubricant eye drops
RxNorm normalized name: carboxymethylcellulose Ophthalmic Solution [Eyes Alive Lubricating]
DrugBank: Carboxymethylcellulose (DB11059)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carboxymethylcellulose-based lubricant eye drops (Refresh OPTIVE® Advanced) administered as needed for 6 months.
Trial: NCT01255046
Drug: Donepezil,
RxNorm normalized name: donepezil, memantine and Ginkgo folium
DrugBank: Donepezil (DB00843)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10mg/tab, 1 tab/day for 72 weeks
Trial: NCT01255046
Drug: STA-1
RxNorm normalized name: 17β-hydroxyandrosta-1,4-dien-3-one
DrugBank: 3,4-dihydroxy-9,10-secoandrosta-1(10),2,4-triene-9,17-dione (DB08542)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300mg/tab, 2 tab/tid for 72 weeks
Trial: NCT01028573
Drug: Miralax mixed with Gatorade
RxNorm normalized name: Miralax
DrugBank: Polyethylene glycol (DB09287)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 238g of PEG-3350 (Miralax) mixed with 2L of Gatorade consumed on the evening before colonoscopy